Drug Approval | March 23, 2024
Zydus receives tentative approval from USFDA for Letermovir Tablets
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Combination shows consistent benefit across prespecified post-progression outcomes
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Operations of Line II was stopped due to a fire incident earlier
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
